『Ozempic, Monjaro, Zepbound - The Arthritis and Autoimmune Disease SECRET Nobody Is Talking About』のカバーアート

Ozempic, Monjaro, Zepbound - The Arthritis and Autoimmune Disease SECRET Nobody Is Talking About

Ozempic, Monjaro, Zepbound - The Arthritis and Autoimmune Disease SECRET Nobody Is Talking About

無料で聴く

ポッドキャストの詳細を見る

What is the power of GLP-1 medications in managing arthritis and autoimmune diseases, without the need for dramatic weight loss?

In this episode, Dr. Diana Girnita, a double board-certified rheumatologist and founder of Rheumatologist OnCall, explores how microdosing Ozempic, Wegovy, Mounjaro, Wegovy and Zepbound can revolutionize treatment plans for those battling persistent inflammation, pain, and flare-ups.

While everyone is talking about these medications, few discuss their potential for arthritis and autoimmune conditions.

Dr. Girnita delves into the research, explaining the differences between semaglutide and tirzepatide, the five mechanisms that combat inflammation independently of weight loss, and the latest insights from 2025 data on conditions like rheumatoid arthritis, psoriatic arthritis, lupus, Sjogren's, osteoarthritis, and gout.

You'll discover:

  • How metabolic inflammation affects biologics and the importance of addressing fat tissue’s inflammatory signals.
  • The groundbreaking 2025 research showing GLP-1 drugs' ability to reduce disease activity and pain without weight loss.
  • The potential of microdosing these medications for patients with uncontrolled autoimmune diseases.
  • The benefits of combining metabolic modulation with conventional therapies to reduce flare-ups and cardiovascular risk.
  • How these findings are reshaping rheumatology practice and future treatment options.

Topics Covered:

  • Differences between Ozempic, Wegovy, Mounjaro, and Zepbound.
  • The role of fat cells in fueling arthritis.
  • Five mechanisms GLP-1 medications use to fight inflammation.
  • The concept and effectiveness of GLP-1 microdosing for arthritis.
  • Insights from 2025 research on various autoimmune conditions and cardiovascular risk.
  • How GLP-1 complements DMARDs and biologics without replacing them.

This episode is ideal for those tired of hitting a plateau, exhausted by constant flare-ups, or healthcare professionals eager to integrate cutting-edge science into patient care. Ignoring this emerging science risks leaving persistent inflammation untreated—missed opportunities that could transform your health.

Join Dr. Girnita in exploring how small changes in medication strategy, driven by the latest science, can unlock significant improvements—beyond weight loss—offering hope, control, and relief from autoimmune chaos.

Are you ready to rethink what’s possible in your autoimmune journey? This isn’t just another episode—it's a paradigm shift in managing inflammation at its core.

Support the show

More info about Dr. Diana Girnita, MD PhD

  • Website: https://rheumatologistoncall.com/
  • Email: Contact@rheumatologistoncall.com
  • Youtube: https://www.youtube.com/@rheumatologistoncall
  • LinkedIn: https://www.linkedin.com/in/diana-girnita-md-phd-07b57810/
  • Instagram: https://www.instagram.com/rheumatologistoncall/
  • Facebook Page: https://www.facebook.com/RheumatologistOncall/
  • Facebook Group: https://www.facebook.com/groups/3685130571554200


adbl_web_anon_alc_button_suppression_t1
まだレビューはありません